巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Galapagos NV

GLPG
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Galapagos NV - 延遲價格・最後更新於 20/01 22:00
最高位
--
最低位
--
開市價
--
前收市價
56.610
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
3,710.94
市盈率
--
息率
--
差價
--
52週高低
113.710 - 46.410
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Galapagos NV
證券代碼
GLPG.US
所屬板塊
Biotechnology
公司業務
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
發行量
65530121
公司總部
Generaal De Wittelaan L11 A3
公司網址
https://www.glpg.com
公司電郵
ir@glpg.com
公司電話
+32 15342900
暫無內容

關於

Galapagos NV(GLPG.US)所屬的行業板塊為Biotechnology。
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
詳細公司背景可參考: https://www.glpg.com